Clinical trials: Individual Difference
Overweight, Obesity
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
This study is open to Chinese adults aged 18 to 60 with overweight or obesity. People can join the study if they have a Body Mass Index from 24 to 40.0 kg/m2.
- Trial name
- NCT06492135
- Testing
- survodutide
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06704724
- Testing
- PF-07985045, Gemcitabine, Nab-paclitaxel
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Pfizer
Hepatic Insufficiency
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
This study is open to adults between 18 and 80 years of age. People with a body mass index (BMI) between 18 and 42 kg/m2 can take part.
- Trial name
- NCT06957756
- Testing
- BI 1584862
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes
This study is comparing the concentration of a single dose of insulin icodec when administered in the belly, upper arm and thigh on different occasions.
- Trial name
- NCT04582448
- Testing
- Insulin icodec
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine
This study will look into a new study medicine called NNC0519-0130 to improve the treatment option for people living with excess body weight or type 2 diabetes or both.
- Trial name
- NCT06642571
- Testing
- NNC0519-0130 B, NNC0519-0130 C
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Healthy
A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities
The main objective of this trial is to evaluate the effects of a single therapeutic and a single supra-therapeutic dose of BI 1015550 following oral administration on cardiac safety parameters in healthy male and female…
- Trial name
- NCT06107036
- Testing
- BI 1015550, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Mild-to-moderate Psoriasis Vulgaris
Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris
The overall purpose of this study is to support the development of a DLX105 topical formulation for the indication mild to moderate psoriasis vulgaris.
- Trial name
- 2011-00500-15 (NCT01595997)
- Testing
- DLX105
- Where
- 2 sites in Austria, Germany
- Volunteers
- 20 people
- Sponsor
- Delenex Therapeutics AG
Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
This study is open to adults with small cell lung cancer and other neuroendocrine tumours that are positive for the tumour marker Delta-like 3 (DLL3).
- Trial name
- NCT05879978
- Testing
- Obrixtamig, Ezabenlimab
- Where
- 8 sites in Belgium, France and 2 more
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection
The main objective of this trial is to compare the pharmacokinetics (PK) of 40 mg BI 695501 100 mg/mL with 40 mg BI 695501 50 mg/mL following single subcutaneous administration.
- Trial name
- NCT05203289
- Testing
- BI 695501 - higher concentration, BI 695501 - lower concentration
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Metastatic Colorectal Cancer (CRC)
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
This study is open to adults with advanced bowel cancer (colorectal cancer) with a KRAS mutation. This is a study in people for whom previous treatment was not successful and surgery is not a treatment option.
- Trial name
- NCT04627142
- Testing
- BI 1701963, Camptosar®
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body
The main objective of this trial is to investigate relative bioavailability of BI 456906 formulation B and BI 456906 formulation C vs. BI 456906 formulation A.
- Trial name
- NCT06772532
- Testing
- BI 456906 - Formulation A, BI 456906 - Formulation B, BI 456906 - Formulation C
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Overweight, Obesity
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity.
- Trial name
- NCT07395687
- Testing
- UBT251
- Where
- 3 sites in United States, Canada
- Volunteers
- 333 people
- Sponsor
- Novo Nordisk A/S
Pulmonary Disease, Chronic Obstructive
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat® on lung function in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with optimal and sub-optimal Peak Inspiratory Flow…
- Trial name
- NCT04223843
- Testing
- Tiotropium + olodaterol
- Where
- 26 sites in United States, Germany
- Volunteers
- 213 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations
The main objective of this trial is to investigate the relative bioavailability of two different formulations of BI 1291583 (test formulations) compared to BI 1291583 reference formulation administered at two different dose…
- Trial name
- NCT06631417
- Testing
- BI 1291583
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.
A Study to Assess the Fed-state Bioequivalence of a Triple Fixed-Combination Drug Product (FCDP) of 2.5 mg Saxagliptin / 5 mg Dapagliflozin / 1000 mg Metformin XR and 5 mg Saxagliptin /10 mg Dapagliflozin /1000 mg Metformin XR…
- Trial name
- NCT03169959
- Testing
- 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Carcinoma, Colorectal Cancer
A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer
In study, liquid biopsy samples will be obtained from non-small cell lung cancer (NSCLC) including Squamous cell carcinoma, Adenocarcinoma and large cell carcinoma, colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma…
- Conditions
- Non-Small-Cell Lung Carcinoma, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05708599
- Testing
- Liquid biopsy
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body
The main objective of this trial is to establish the bioequivalence of two different formulations of vicadrostat / empagliflozin in healthy male and female trial participants following oral administration.
- Trial name
- NCT07845630
- Testing
- Vicadrostat, Empagliflozin, Vicadrostat + empagliflozin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Solid Tumors
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists.
- Trial name
- NCT05471856
- Testing
- BI 1703880, Ezabenlimab
- Where
- 20 sites in United States, Japan and 4 more
- Volunteers
- 66 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis, Healthy Volunteers
A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.
The study will try, in 2 separate parts, each using 12 research subjects, to see how a new form of the pill CE 224,535 gets released into the bloodstream and whether that is affected by food.
- Trial name
- NCT00838058
- Testing
- CE-224,535, CE 224,535
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood
The main objective of this trial is to investigate: the relative bioavailability of Avenciguat (BI 685509) TF2 (Reference, R) vs.
- Trial name
- NCT06193811
- Testing
- Avenciguat (BI 685509) (intended commercial formulation (iCF)), Avenciguat (BI 685509) (trial formulation 2 (TF2)), esomeprazole
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim